Seven Peptides, One Repair Story — Tracked and Cited

The short version

bigfootpeptides is a reporter's notebook on seven peptides studied for tissue repair — mending tendons, calming an inflamed gut, healing skin, and growing new blood vessels back into damaged tissue. Three are single compounds: BPC-157 (a stomach-derived repair peptide), TB-500 (a fragment of a cell-movement protein called thymosin beta-4), and GHK-Cu (a copper-carrying tripeptide long used in skincare) and KPV (a small anti-inflammatory piece of a hormone). Three more are research-community blends that combine those building blocks: Wolverine (BPC-157 + TB-500), KLOW (four peptides together), and GLOW (three peptides, aimed more at skin).

Each page here follows the same rule: every number, every study result, and every claim from the research literature carries a citation you can check. Where people in research-use communities report an effect but no controlled human study backs it up, we say so in plain words — anecdotal, not clinical evidence — every time. Nothing here is a dose, a prescription, or medical advice.

The big picture of repair peptide research

Every peptide on this site earns its place because of a distinct pathway in the body's repair toolkit. BPC-157 is the anchor — a synthetic fragment of a protein first identified in human gastric juice, best known in the literature for up-regulating the VEGFR2 receptor and switching on the VEGFR2-Akt-eNOS signaling chain that grows new blood vessels into damaged tissue ^[4]. TB-500 approaches repair from inside the cell: it's built around the actin-binding motif of thymosin beta-4, a protein that binds and releases the cell's internal scaffolding so cells can migrate into a wound ^[10]. GHK-Cu works at the level of the genome and the extracellular matrix — a 2018 gene-expression analysis found it shifts the activity of roughly 31% of measured human genes, tilted toward tissue-repair, antioxidant, and DNA-repair programs ^[14]. KPV takes the anti-inflammatory route: it's the tail end of a hormone (alpha-MSH) that calms NF-kB inflammatory signaling and gets pulled directly into gut tissue through a transporter called PepT1 ^[20]. The three blends — Wolverine, KLOW, and GLOW — are the research community's attempt to stack these mechanisms together. None of the three has ever been tested as a blend in a controlled study; every claim about them is an extrapolation from the single-compound research, and we say so on every blend page.

What are research peptides, exactly?

Peptides are short chains of amino acids — smaller than a full protein, but built from the same twenty-ish letters. The compounds tracked on this site are studied almost entirely in cell cultures and animal models, with human evidence ranging from thin (BPC-157: three small pilot studies as of a 2025 review ^[2]) to nonexistent (TB-500 as a fragment, KPV, and all three blends). None is an FDA-approved medicine. They are sold by research suppliers strictly for laboratory use, not for human consumption, and nothing on this site describes, recommends, or implies a human dose. Where a study reports a dose, we report it exactly as the study used it — in the species that was actually dosed, not as a suggestion for a reader.

How this site reads the evidence

Three rules run through every page here. First, a quantitative claim — a percentage, a half-life, a sample size — always carries a citation number you can trace on the references page. Second, when the source is a research-community forum post rather than a study, we call it what it is: anecdotal, not clinical evidence, every single time, with no exceptions for the compounds that don't have much else to go on. Third, we name the gaps as plainly as the findings — where a review says the human data are thin, or where a blend has literally never been tested as a blend, that's on the page, not buried in a footnote. Nothing here recommends a dose, a use, or a source.